Biostatistics and Bioinformatics Department Metrics

View the grants and publications from the Department of Biostatistics and Bioinformatics.

Grants
  • Moffitt Imaging Biomarker Validation Center
    Sponsor: Nat Institutes of Health
    PI (Contact):Lee, J.,PI:Gillies, R.,PI:Heine, J.,PI:Schabath, M.
  • (00014262) Mechanisms of Radioresistance and Strategies for Radiosensitization in Ovarian Clear Cell Carcinoma
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • A Vicious Cycle of Pyroptotic Cancer Cells and Fibroblasts Fuels Chemoresistance
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Curated Prostate Cancer Data for Novel and Reproducible Prognostic Modeling
    Sponsor: Nat Institutes of Health
    PI:Fridley, B.
  • Clinical Validation of APC and TP53 as Biomarkers for Cetuximab Response
    Sponsor: Nat Institutes of Health
    PI:Schell, M.
  • Targeting Tumor Repopulation and the Immune Microenvironment to Overcome Chemoresistance
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Decoding Tobacco-Related Oral Cancer Ecosystem by Integrative Approach
    Sponsor: Nat Institutes of Health
    PI (Contact):Tan, A.,PI (MPI):Chung, C.
  • Investigating the prognostic role of intrinsic immune evasion mechanisms in HNSCC
    Sponsor: Nat Institutes of Health
    PI:Wang, X.
  • Reduction of Lethal Prostate Cancer Disparities in Underserved Hispanic/Latino Populations
    Sponsor: US Army
    PI:Teer, J.
  • Biological Determinants of Colorectal Cancer Outcomes in Latinos of Diverse Ancestral Origins
    Sponsor: Nat Institutes of Health
    PI:Teer, J.
  • Tampa Bay Life Sciences Computing Commons (TBLSCC)
    Sponsor: Nat Institutes of Health
    PI:Eschrich, S.
  • AOST-1822, Protocol OST31-164-01, An Open-Label Phase 2 Study of Maintenance Therapy with OST31-164 After Resection with Recurrent Osteosarcoma
    Sponsor: Children's Oncology Group
    PI:Fridley, B.
  • Epigenetic Regulation of the Immune Synapse in Melanoma
    Sponsor: US Army
    PI:Berglund, A.
  • Research Digital Slide Archive for Immunohistochemical Staining and Tissue Microarray Applications
    Sponsor: Moffitt Fdtn
    PI:Eschrich, S.,CO-PI:Johnson, J.
  • Research Digital Slide Archive for Immunohistochemical Staining and Tissue Microarray Applications
    Sponsor: Moffitt Cancer Center
    PI:Eschrich, S.,CO-PI:Johnson, J.
  • Analytical Tools for Studying the Tumor Microenvironment Leveraging Spatial Transcriptomics
    Sponsor: Nat Institutes of Health
    PI:Fridley, B.
  • Innovative Proteogenomics to Investigate Tertiary Lymphoid Structures in Lung Cancer
    Sponsor: Cancer Research Institute
    PI:Stewart, P.
Publications
  • Yang MJ, Sutton SK, Hernandez LM, Jones SR, Wetter DW, Kumar S, Vinci C. A Just-In-Time Adaptive intervention (JITAI) for smoking cessation: Feasibility and acceptability findings. Addictive Behaviors. 2023 Jan.136:107467. Pubmedid: 36037610.
  • Yang MJ, Brandon KO, Sutton SK, Kleinjan M, Sawyer LE, Brandon TH, Vinci C. Augmented reality as a novel approach for addiction treatment: development of a smoking cessation app. Ann Med. 2022 Dec.54(1):3096-3106. Pubmedid: 36345961. Pmcid: PMC9648377.
  • Szwarc MM, Hai L, Maurya VK, Rajapakshe K, Perera D, Ittmann MM, Mo Q, Lin Y, Bettini ML, Coarfa C, Lydon JP. Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus. Cytokine. 2022 Dec.160:156022. Pubmedid: 36099756.
  • Xia BT, Otto AK, Allenson K, Kocab M, Fan W, Mo Q, Denbo JW, Malafa MP, Permuth JB, Kim DW, Fleming JB, Reblin M, Hodul PJ. Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. J Behav Med. 2022 Dec.45(6):935-946. Pubmedid: 35986871.
  • Brown L, Carr MJ, Sam C, Sun W, Whiting J, Kim Y, Lee MC. Tolerance and Outcomes of Neoadjuvant Chemotherapy in Geriatric Breast Cancer Patients. J Surg Res. 2022 Nov.283:329-335. Pubmedid: 36427442.
  • Huelster HL, Zemp L, Turner K, Gonzalez BD, Jim H, Gore LR, Gilbert SM. Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility. J Urol. 2022 Nov. Pubmedid: 36350586.
  • Sarcar B, Fang B, Izumi V, Nunez-Lopez Y, Tassielli A, Pratley R, Jeong D, Permuth JB, Koomen JM, Fleming JB, Stewart PA. A comparative proteomics analysis identified differentially expressed proteins in pancreatic cancer-associated stellate cell small extracellular vesicles. Mol Cell Proteomics. 2022 Nov.100438. Pubmedid: 36332889.
  • Hathaway CA, Wang T, Townsend MK, Vinci C, Jake-Schoffman DE, Saeed-Vafa D, Moran Segura C, Nguyen JV, Conejo-Garcia JR, Fridley BL, Tworoger SS. Lifetime Exposure to Cigarette Smoke and Risk of Ovarian Cancer by T Cell Tumor Immune Infiltration. Cancer Epidemiol Biomarkers Prev. 2022 Nov. Pubmedid: 36318652.
  • Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, Li D, Park W, Kim RD. Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. Eur J Cancer. 2022 Nov.176:171-180. Pubmedid: 36252287.
  • Barata A, Hoogland AI, Small BJ, Acevedo KI, Antoni MH, Gonzalez BD, Jacobsen PB, Lechner SC, Tyson DM, Meade CD, Rodriguez Y, Salsman JM, Sherman AC, Sutton SK, Jim HSL. Spiritual well-being, distress and quality of life in Hispanic women diagnosed with cancer undergoing treatment with chemotherapy. Psychooncology. 2022 Nov.31(11):1933-1940. Pubmedid: 36121699.
  • Kim KB, Kim DW, Kim Y, Tang J, Kirk N, Gan Y, Kim B, Fang B, Park JL, Zheng Y, Park KS. WNT5A-RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer. Cancer Res. 2022 Nov.82(22):4219-4233. Pubmedid: 36102736. Pmcid: PMC9669186.
  • Zhang J, Gallaher J, Cunningham JJ, Choi JW, Ionescu F, Chatwal MS, Jain R, Kim Y, Wang L, Brown JS, Anderson AR, Gatenby RA. A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358643. Pmcid: PMC9656891.
  • Schell MJ, Gwede CK, Friedman M. Physician Adenoma Detection Rates and Colorectal Cancer. Jama. 2022 Oct.328(14):1462. Pubmedid: 36219411.
  • Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 Oct. Pubmedid: 36215121.
  • Reblin M, D'Almeida H, Barrios-Monroy V, McCormick R, Rodriguez L, Walters K, Sutton SK, Zebrack B, Forsyth P, Byrne MM, Wells KJ. Training cancer caregiver navigators: experiences from implementing the eSNAP and caregiver navigator intervention. Support Care Cancer. 2022 Oct. Pubmedid: 36207640. Pmcid: PMC9546415.
  • Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA, Prieto K, Chen A, Smalley KSM, Czerniecki B, Forsyth P, Koya RC, Ruffell B, Cubillos-Ruiz JR, Munn DH, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022 Oct.40(10):1145-1160.e9. Pubmedid: 36150390. Pmcid: PMC9561067.
  • Eakins RA, Chobrutskiy A, Teer JK, Patel DN, Hsiang M, Huda TI, Zaman S, Sexton WJ, Coppola D, Falasiri S, Blanck G, Chobrutskiy BI. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. Mol Immunol. 2022 Oct.150:58-66. Pubmedid: 35987136.
  • Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunol Res. 2022 Oct.10(10):1263-1279. Pubmedid: 35969234.
  • Kuykendall AT, Mo Q, Sallman DA, Ali NA, Chan O, Yun S, Sweet KL, Padron E, Lancet JE, Komrokji RS. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022 Oct.128(19):3495-3501. Pubmedid: 35942592.
  • Calderon-Casellas C, Lacson JCA, Forgas SM, Doyle SH, Del Rio J, Feliciano AR, Kim Y, Roetzheim RG, Sutton SK, Vadaparampil ST, Soto-Torres B, Kanetsky PA. Assessment of skin cancer precision prevention materials among Hispanics in Florida and Puerto Rico. Patient Educ Couns. 2022 Oct.105(10):3143-3150. Pubmedid: 35778318.
  • Rappold PM, Vuong L, Leibold J, Chakiryan NH, Curry M, Kuo F, Sabio E, Jiang H, Nixon BG, Liu M, Berglund AE, Silagy AW, Mascareno A, Golkaram M, Marker M, Reising A, Savchenko A, Millholland JM, Chen YB, Russo P, Coleman J, Reznik E, Manley BJ, Ostrovnaya I, Makarov V, DiNatale RG, Blum KA, Ma X, Chowell D, Li MO, Solit DB, Lowe SW, Chan TA, Motzer RJ, Voss MH, Hakimi AA. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022 Oct.12(10):2308-2329. Pubmedid: 35758895.
  • Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
  • Dickey BL, Nedjai B, Preece MD, Schell MJ, Boulware D, Whiting J, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Kennedy K, Chung CH, Giuliano AR. Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer. Cancer Med. 2022 Oct.11(20):3735-3742. Pubmedid: 35619332. Pmcid: PMC9582688.
  • Medina-Ramirez P, Casas L, Sutton SK, Calixte-Civil P, Brandon KO, Martinez U, Meade CD, Byrne MM, Brandon TH, Simmons VN. Hispanic/Latinx Ethnic Subgroup Differences in Sociodemographic, Sociocultural, and Smoking Characteristics in a Cessation Trial: An Exploratory Study. Nicotine Tob Res. 2022 Oct.24(10):1589-1596. Pubmedid: 35366328. Pmcid: PMC9575968.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
  • Thompson ZJ, Teer JK, Li J, Chen Z, Welsh EA, Zhang Y, Ayoubi N, Eroglu Z, Tan AC, Smalley KSM, Chen YA. Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment. Cells. 2022 Sep.11(18). Pubmedid: 36139469. Pmcid: PMC9497118.
  • Yang MJ, Yepez VV, Brandon KO, Reblin M, Pidala J, Jim HSL, Meyer JS, Gore LR, Khera N, Lau P, Sauls RM, Jones SR, Vinci C. Correction: A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial. PLoS One. 2022 Sep.17(9):e0275398. Pubmedid: 36149879. Pmcid: PMC9506639.
  • Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, Crimella J, Sansil S, Thapa R, Fridley BL, Llosa N, Badgett T, Gorlick R, Reed D, Gill J. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Med. 2022 Sep. Pubmedid: 36151773.
  • Huang BJ, Smith JL, Farrar JE, Wang YC, Umeda M, Ries RE, Leonti AR, Crowgey E, Furlan SN, Tarlock K, Armendariz M, Liu Y, Shaw TI, Wei L, Gerbing RB, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Rubnitz J, Ma J, Klco JM, Ma X, Alonzo TA, Triche T, Meshinchi S. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nat Commun. 2022 Sep.13(1):5487. Pubmedid: 36123353. Pmcid: PMC9485122.
  • Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
  • Ding W, Wang C, Narita Y, Wang H, Leong MML, Huang A, Liao Y, Liu X, Okuno Y, Kimura H, Gewurz B, Teng M, Jin S, Sato Y, Zhao B. The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines. J Virol. 2022 Sep.96(18):e0073922. Pubmedid: 36094314. Pmcid: PMC9517713.
  • Skinner A, Buhlmann M, Fridley BL, Reed DR, Vicedo D, Mason NT. Pilot Study in Investigating Material Financial Toxicity Markers by Age in Cancer Patients. J Adolesc Young Adult Oncol. 2022 Sep. Pubmedid: 36094443.
  • Zota V, Siegal GP, Kelly D, Bridge JA, Berglund A, Bui K, Khalil F, R Reed D, Altiok S, Magliocco A, Bui MM. Validation of PRKCB Immunohistochemistry as a Biomarker for the Diagnosis of Ewing Sarcoma. Fetal Pediatr Pathol. 2022 Sep.1-12. Pubmedid: 36062956.
  • Anadon CM, Zhang C, Wang X, Cen L, Conejo-Garcia JR, Yu X. Protocol for the isolation of CD8+ tumor-infiltrating lymphocytes from human tumors and their characterization by single-cell immune profiling and multiome. STAR Protoc. 2022 Sep.3(3):101649. Pubmedid: 36065294. Pmcid: PMC9440482.
  • Xu X, Wang K, Vera O, Verma A, Jasani N, Bok I, Elemento O, Du D, Yu X, Karreth FA. Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis. Cancer Res. 2022 Sep.82(17):3016-3031. Pubmedid: 36052492.
  • Sutton SK, Brandon KO, Harrell PT, Martínez Ú, Simmons VN, Gore LR, Bullen CR, Brandon TH. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction. 2022 Sep.117(9):2493-2503. Pubmedid: 35491736.
  • Amorrortu RP, Zhao Y, Fenske NA, Cherpelis BS, Messina JL, Giuliano AR, Sondak VK, Schell MJ, Mckay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections. J Infect Dis. 2022 Sep.226(7):1162-1174. Pubmedid: 35022780. Pmcid: PMC9518839.
  • Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, Farma JM, Hotz M, Deneve J, Fleming M, Bartlett EK, Sharma A, Dossett L, Hughes T, Gyorki DE, Downs J, Karakousis G, Song Y, Lee A, Berman RS, van Akkooi A, Stahlie E, Han D, Vetto J, Beasley G, Farrow NE, Hui JYC, Moncrieff M, Nobes J, Baecher K, Perez M, Lowe M, Ollila DW, Collichio FA, Bagge RO, Mattsson J, Kroon HM, Chai H, Teras J, Sun J, Carr MJ, Tandon A, Babacan NA, Kim Y, Naqvi M, Zager J, Khushalani NI. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. J Immunother Cancer. 2022 Aug.10(8). Pubmedid: 36002183. Pmcid: PMC9413295.
  • Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022 Aug.15(747):eabj5879. Pubmedid: 35973030. Pmcid: PMC9528501.
  • Xu X, Wang K, Vera O, Verma A, Jasani N, Bok I, Elemento O, Du D, Yu X, Karreth FA. Gain of chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis. Cancer Res. 2022 Aug. Pubmedid: 35820070.
  • Jiang C, Ward NP, Prieto-Farigua N, Kang YP, Thalakola A, Teng M, DeNicola GM. Corrigendum to "A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer" [Redox Biol. 54 (2022) 102358]. Redox Biol. 2022 Aug.54:102393. Pubmedid: 35794066. Pmcid: PMC9287741.
  • Crowder SL, Buro AW, Lacson JCA, Kim Y, Sutton SK, Roetzheim RG, Vadaparampil ST, Stern M, Kanetsky PA. Retention and Evaluation of Precision and Generic Prevention Materials for Melanoma: A Qualitative Study Comparing Young Adults and Adults. Cancer Prev Res (Phila). 2022 Aug.15(8):533-542. Pubmedid: 35665800. Pmcid: PMC9357111.
  • Jiang C, Ward NP, Prieto-Farigua N, Kang YP, Thalakola A, Teng M, DeNicola GM. A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer. Redox Biol. 2022 Aug.54:102358. Pubmedid: 35667246. Pmcid: PMC9168196.
  • Fasching PA, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, Ekici AB, Reis A, Schneeweiss A, Tesch H, Fehm TN, Heinrich G, Beckmann MW, Ruebner M, Huebner H, Lambrechts D, Madden E, Shen J, Romm J, Doheny K, Jenkins GD, Carlson EE, Li L, Fridley BL, Cunningham JM, Janni W, Monteiro ANA, Schaid DJ, Häberle L, Weinshilboum RM, Wang L. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clin Cancer Res. 2022 Aug.28(15):3342-3355. Pubmedid: 35653140. Pmcid: PMC9357161.
  • Jain MD, Ziccheddu B, Coughlin CA, Faramand RG, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini MO, Landgren O, Davila ML, Schatz JH, Locke FL, Maura F. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022 Aug.140(5):491-503. Pubmedid: 35476848. Pmcid: PMC9353150.
  • Mehta R, Frakes J, Kim J, Nixon A, Liu Y, Howard L, Martinez Jimenez ME, Carballido E, Imanirad I, Sanchez J, Dessureault S, Xie H, Felder S, Sahin I, Hoffe S, Malafa M, Kim R. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist. 2022 Aug.27(8):621-e617. Pubmedid: 35325225. Pmcid: PMC9355805.
  • Selfridge JM, Sinner HF, Whiting J, Sun W, Mallory MA, Hoover SJ, Kiluk JV, Khakpour N, Czerniecki BJ, Laronga C, Mo Q, Lee MC. Effect of Microporous Polysaccharide Particles in Patients Undergoing Mastectomy. Clin Breast Cancer. 2022 Jul. Pubmedid: 36055918.
  • Yang MJ, Brandon KO, Sutton SK, Kleinjan M, Hernandez LM, Sawyer LE, Brandon TH, Vinci C. Augmented reality for extinction of cue-provoked urges to smoke: Proof of concept. Psych Addic Behav. 2022 Jul. Pubmedid: 35834198.
  • Tan ES, Fan W, Knepper TC, Schell MJ, Sahin IH, Fleming JB, Xie H. Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer. Target Oncol. 2022 Jul.17(4):483-492. Pubmedid: 35767139.
  • Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul.169:93-102. Pubmedid: 35526308.
  • Lake PW, Conley CC, Pal T, Sutton SK, Vadaparampil ST. Anxiety and depression among Black breast cancer survivors: Examining the role of patient-provider communication and cultural values. Patient Educ Couns. 2022 Jul.105(7):2391-2396. Pubmedid: 35440374.
  • Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
  • Coghill AE, Kim Y, Hodge JM, Bender N, Smith-Warner SA, Teras LR, Grimsrud TK, Waterboer T, Egan KM. Prospective investigation of herpesvirus infection and risk of glioma. Int J Cancer. 2022 Jul.151(2):222-228. Pubmedid: 35225352.
  • Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35676062. Pmcid: PMC9185557.
  • Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, Doench JG, O'Reilly RJ, Cesarman E, Giulino-Roth L, Gewurz BE. Author Correction: DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2022 Jun.7(6):928. Pubmedid: 35505195.
  • Peres LC, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton O, Alsina M, Brayer J, Blue B, Baz R, Siqueira Silva A, Nishihori T, Shain KH, Gillis N. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022 Jun.6(12):3767-3778. Pubmedid: 35500227. Pmcid: PMC9631567.
  • Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Jun.28(11):2329-2338. Pubmedid: 35344035. Pmcid: PMC9167762.
  • Reblin M, Wells KJ, Otto A, McCormick R, Rodriguez L, Walters K, Sutton SK, Zebrack B, Forsyth P, Byrne MM. Addressing a critical need for caregiver support in neuro-oncology: development of a caregiver navigation intervention using eSNAP social resource visualization. Support Care Cancer. 2022 Jun.30(6):5361-5370. Pubmedid: 35290512. Pmcid: PMC8922391.
  • Chatzkel J, Schell MJ, Chahoud J, Zhang J, Jain R, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clin Genitourin Cancer. 2022 Jun.20(3):252-259. Pubmedid: 35249821.
  • Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Jun.28(11):2313-2320. Pubmedid: 35254415. Pmcid: PMC9167697.
  • Zhang Y, Seminario-Vidal L, Cohen L, Hussaini M, Yao J, Rutenberg D, Kim Y, Giuliano A, Robinson LA, Sokol L. "Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides". Front Cell Infect Microbiol. 2022 May.12:850509. Pubmedid: 35656034. Pmcid: PMC9152451.
  • Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
  • Sasamoto N, Stewart PA, Wang T, Yoder SJ, Chellappan S, Hecht JL, Fridley BL, Terry KL, Tworoger SS. Lifetime ovulatory years and ovarian cancer gene expression profiles. J Ovarian Res. 2022 May.15(1):59. Pubmedid: 35562768. Pmcid: PMC9102743.
  • Lacson JCA, Forgas SM, Doyle SH, Qian L, Del Rio J, Valavanis S, Carvajal R, Gonzalez-Calderon G, Kim Y, Roetzheim RG, Vadaparampil ST, Kanetsky PA. Assessment of melanoma precision prevention materials incorporating MC1R genetic risk information. Transl Behav Med. 2022 May.12(5):683-687. Pubmedid: 35552458. Pmcid: PMC9274978.
  • Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494. Pmcid: PMC9096229.
  • Christy SM, Sutton SK, Abdulla R, Boxtha C, Gonzalez P, Cousin L, Ewing A, Montoya S, Lopez D, Beehler T, Sanchez J, Carvajal R, Meade CD, Gwede CK. A multilevel, low literacy dual language intervention to promote colorectal cancer screening in community clinics in Florida: A randomized controlled trial. Prev Med. 2022 May.158:107021. Pubmedid: 35305995. Pmcid: PMC9018599.
  • Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022 May.8(5):748-754. Pubmedid: 35266953. Pmcid: PMC8914884.
  • Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Moran Segura C, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund AE, Sokol L, Zhang J, Rodriguez PC, Mule JJ, Futreal AP, Tsai KY, Chen PL. Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discov. 2022 May.12(5):1294-1313. Pubmedid: 35247891. Pmcid: PMC9148441.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Peres LC, Colin-Leitzinger C, Sinha S, Marks JR, Conejo-Garcia JR, Alberg AJ, Bandera EV, Berchuck A, Bondy ML, Christensen BC, Cote ML, Doherty JA, Moorman PG, Peters ES, Moran Segura C, Nguyen JV, Schwartz AG, Terry PD, Wilson CM, Fridley BL, Schildkraut JM. Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 May.31(5):1006-1016. Pubmedid: 35244678. Pmcid: PMC9081269.
  • Yu X, Cen L, Chen YA, Markowitz J, Shaw TI, Tsai KY, Conejo-Garcia JR, Wang X. Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Res. 2022 May.82(9):1724-1735. Pubmedid: 35176128. Pmcid: PMC9064917.
  • Buras AL, Wang T, Whiting J, Townsend MK, Fridley BL, Tworoger SS. Prospective Analyses of Sedentary Behavior in Relation to Risk of Ovarian Cancer. Am J Epidemiol. 2022 May.191(6):1021-1029. Pubmedid: 35094053. Pmcid: PMC9271222.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
  • Tan ES, Knepper TC, Wang X, Permuth JB, Wang L, Fleming JB, Xie H. Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. Cancers (Basel). 2022 Apr.14(9). Pubmedid: 35565354. Pmcid: PMC9101426.
  • Pérez-Morales J, Lu H, Mu W, Tunali I, Kutuk T, Eschrich SA, Balagurunathan Y, Gillies RJ, Schabath MB. Volume doubling time and radiomic features predict tumor behavior of screen-detected lung cancers. Cancer Biomark. 2022 Apr.33(4):489-501. Pubmedid: 35491768. Pmcid: PMC9310661.
  • Permuth JB, Mesa T, Williams SL, Cardentey Y, Zhang D, Pawlak EA, Li J, Cameron ME, Ali KN, Jeong D, Yoder SJ, Chen DT, Trevino JG, Merchant N, Malafa M. A pilot study to troubleshoot quality control metrics when assessing circulating miRNA expression data reproducibility across study sites. Cancer Biomark. 2022 Apr.33(4):467-478. Pubmedid: 35491771. Pmcid: PMC9428925.
  • Wood AC, Zhang Y, Mo Q, Cen L, Fontaine J, Hoffe SE, Frakes J, Dineen SP, Pimiento JM, Walko CM, Mehta R. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. Oncologist. 2022 Apr.27(4):307-313. Pubmedid: 35380714. Pmcid: PMC8982441.
  • Yang MJ, Yepez VV, Brandon KO, Reblin M, Pidala J, Jim HSL, Meyer JS, Gore LR, Khera N, Lau P, Sauls RM, Jones SR, Vinci C. A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial. PLoS One. 2022 Apr.17(4):e0266316. Pubmedid: 35363799. Pmcid: PMC8975158.
  • Mahajan S, Majumder A, Stewart PA, Chen YA, Adhikari E, Fang B, Yang Y, Lawrence H, Kinose F, Koomen JM, Haura EB. Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer. Acs Chem Biol. 2022 Apr.17(4):776-784. Pubmedid: 35311290.
  • Ospina OE, Wilson CM, Soupir AC, Berglund A, Smalley I, Tsai KY, Fridley B. spatialGE: quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics. 2022 Apr.38(9):2645-2647. Pubmedid: 35258565.
  • Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
  • Berglund A, Muenyi C, Siegel EM, Ajidahun A, Eschrich SA, Wong D, Hendrick LE, Putney RM, Kim S, Hayes DN, Shibata D. Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell Carcinomas. Cancer Epidemiol Biomarkers Prev. 2022 Apr.31(4):858-869. Pubmedid: 35064062. Pmcid: PMC8983563.
  • Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, Boyle TA, Meyer AS, Koomen JM, Haura EB. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. Mol Cancer Res. 2022 Apr.20(4):542-555. Pubmedid: 35022314. Pmcid: PMC8983558.
  • Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss. Clin Genitourin Cancer. 2022 Apr.20(2):e158-e165. Pubmedid: 34974985.
  • Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies. Stat Med. 2022 Apr.41(8):1361-1375. Pubmedid: 34897773.
  • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
  • Tan E, Whiting J, Knepper T, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Permuth JB, Somerer K, Kim R, Anaya DA, Fleming JB, Walko C, Sahin IH. Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. Am J Clin Oncol. 2022 Apr.45(4):137-141. Pubmedid: 35320814.
  • Liu X, Zhao B, Shaw TI, Fridley BL, Duckett DR, Tan AC, Teng M. Summarizing internal dynamics boosts differential analysis and functional interpretation of super enhancers. Nucleic Acids Res. 2022 Apr.50(6):3115-3127. Pubmedid: 35234924. Pmcid: PMC8989535.
  • Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nat Commun. 2022 Mar.13(1):1487. Pubmedid: 35347124. Pmcid: PMC8960844.
  • Vidrine JI, Shih YT, Businelle MS, Sutton SK, Hoover DS, Cottrell-Daniels C, Fennell BS, Bowles KE, Vidrine DJ. Comparison of an automated smartphone-based smoking cessation intervention versus standard quitline-delivered treatment among underserved smokers: protocol for a randomized controlled trial. BMC Public Health. 2022 Mar.22(1):563. Pubmedid: 35317789. Pmcid: PMC8939152.
  • Mitchell JR, Szepietowski P, Howard R, Reisman P, Jones JD, Lewis P, Fridley BL, Rollison DE. A Question-and-Answer System to Extract Data From Free-Text Oncological Pathology Reports (CancerBERT Network): Development Study. J Med Internet Res. 2022 Mar.24(3):e27210. Pubmedid: 35319481. Pmcid: PMC8987958.
  • Yang M, Davis TB, Pflieger L, Nebozhyn MV, Loboda A, Wang H, Schell MJ, Thota R, Pledger WJ, Yeatman TJ. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. BMC Cancer. 2022 Mar.22(1):256. Pubmedid: 35272617. Pmcid: PMC8908604.
  • Tan E, Whiting J, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Walko C, Permuth JB, Sommerer K, Kim R, Anaya DA, Fleming JB, Sahin IH. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. Oncologist. 2022 Mar.27(3):191-197. Pubmedid: 35274712. Pmcid: PMC8914499.
  • Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson ARA, Saglam O, Conejo-Garcia JR. IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Res. 2022 Mar.82(5):859-871. Pubmedid: 34949671. Pmcid: PMC8898267.
  • Simmons VN, Sutton SK, Medina-Ramirez P, Martinez U, Brandon KO, Byrne MM, Meade CD, Meltzer LR, Brandon TH. Self-help smoking cessation intervention for Spanish-speaking Hispanics/Latinxs in the United States: A randomized controlled trial. Cancer. 2022 Mar.128(5):984-994. Pubmedid: 34679188. Pmcid: PMC9254161.
  • Walton K, Walker K, Riddle M, Koehn BH, Reff J, Sagatys EM, Linden MA, Pidala J, Kim J, Lee MC, Kiluk JV, Hui JYC, Yun SY, Xing Y, Stefanski H, Lawrence HR, Lawrence NJ, Tolar J, Anasetti C, Blazar BR, Sebti SM, Betts BC. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. Am J Transplant. 2022 Mar.22(3):717-730. Pubmedid: 34668635. Pmcid: PMC8897228.
  • Lee BD, Gitter A, Greene CS, Raschka S, Maguire F, Titus AJ, Kessler MD, Lee AJ, Chevrette MG, Stewart PA, Britto-Borges T, Cofer EM, Yu KH, Carmona JJ, Fertig EJ, Kalinin AA, Signal B, Lengerich BJ, Triche TJ, Boca SM. Ten quick tips for deep learning in biology. PLoS Comput Biol. 2022 Mar.18(3):e1009803. Pubmedid: 35324884. Pmcid: PMC8946751.
  • Wilson C, Soupir AC, Thapa R, Creed J, Nguyen J, Segura CM, Gerke T, Schildkraut JM, Peres LC, Fridley BL. Tumor immune cell clustering and its association with survival in African American women with ovarian cancer. PLoS Comput Biol. 2022 Mar.18(3):e1009900. Pubmedid: 35235563. Pmcid: PMC8920290.
  • Vinci C, Hemenway M, Baban SS, Yang MJ, Brandon KO, Witkiewitz K, Unrod M, Brandon TH, Wetter DW, Sutton SK. Transition to telehealth: Challenges and benefits of conducting group-based smoking and alcohol treatment virtually. Contemp Clin Trials. 2022 Mar.114:106689. Pubmedid: 35085833. Pmcid: PMC8785408.
  • Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, Yang Y. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021. Emerg Infect Dis. 2022 Mar.28(3):556-563. Pubmedid: 35081021. Pmcid: PMC8888241.
  • Ferrall-Fairbanks MC, Chakiryan N, Chobrutskiy BI, Kim Y, Teer JK, Berglund A, Mulé JJ, Fournier M, Siegel EM, Dhillon J, Falasiri SSA, Arturo JF, Katende EN, Blanck G, Manley BJ, Altrock PM. Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Res. 2022 Mar.82(5):929-942. Pubmedid: 35031572. Pmcid: PMC8898280.
  • Samanic CM, Teer JK, Thompson ZJ, Creed JH, Fridley BL, Burt Nabors L, Williams SL, Egan KM. Mitochondrial DNA sequence variation and risk of glioma. Mitochondrion. 2022 Mar.63:32-36. Pubmedid: 35032707. Pmcid: PMC8885975.
  • Kim J, Lee JH. A novel graphical evaluation of agreement. BMC Med Res Methodol. 2022 Feb.22(1):51. Pubmedid: 35184729. Pmcid: PMC8858529.
  • Tomaszewski MR, Fan S, Garcia A, Qi J, Kim Y, Gatenby RA, Schabath MB, Tap WD, Reinke DK, Makanji RJ, Reed DR, Gillies RJ. AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance. Tomography. 2022 Feb.8(1):341-355. Pubmedid: 35202193. Pmcid: PMC8880510.
  • Bag A, Schultz A, Bhimani S, Stringfield O, Dominguez W, Mo Q, Cen L, Adeegbe D. Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. Oncoimmunology. 2022 Feb.11(1):2042065. Pubmedid: 35223194. Pmcid: PMC8865306.
  • Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. Ann Surg Oncol. 2022 Feb.29(2):804-805. Pubmedid: 34817772.
  • McLeod KL, Skinner AM, Beaupin LK, Vadaparampil ST, Fridley BL, Reed DR. Clinical Trial Availability by Location for 1000 Simulated AYA Patients. J Adolesc Young Adult Oncol. 2022 Feb.11(1):95-103. Pubmedid: 33983850. Pmcid: PMC8864422.
  • Obermayer A, Dong L, Hu Q, Golden M, Noble JD, Rodriguez P, Robinson TJ, Teng M, Tan AC, Shaw TI. DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets. Biology (Basel). 2022 Feb.11(2). Pubmedid: 35205126. Pmcid: PMC8869715.
  • Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS One. 2022 Feb.17(2):e0264014. Pubmedid: 35226658. Pmcid: PMC8884513.
  • Shabani S, Turner K, Nichols AC, Wang X, Patel KB. A Review of Health Care Disparities in Head and Neck Squamous Cell Carcinomas. J Health Care Poor Underserved. 2022 Feb.33(1):478-491. Pubmedid: 35153235.
  • Wei G, Teng M, Rosa M, Wang X. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes. Breast Cancer Res. 2022 Feb.24(1):11. Pubmedid: 35135604. Pmcid: PMC8822747.
  • Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Ann Surg Oncol. 2022 Feb.29(2):791-801. Pubmedid: 34648098.
  • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
  • Lacson JCA, Doyle SH, Del Rio J, Forgas SM, Carvajal R, Gonzalez-Calderon G, Feliciano AR, Kim Y, Roetzheim RG, Sutton SK, Vadaparampil ST, Soto-Torres B, Kanetsky PA. A randomized clinical trial of precision prevention materials incorporating MC1R genetic risk to improve skin cancer prevention activities among Hispanics. Cancer Res Commun. 2022 Jan.2(1):28-38. Pubmedid: 35845857. Pmcid: PMC9286490.
  • Buro AW, Baskin M, Miller D, Ward T, West DS, Gore LR, Gwede CK, Epel E, Carson TL. Rationale and study protocol for a randomized controlled trial to determine the effectiveness of a culturally relevant, stress management enhanced behavioral weight loss intervention on weight loss outcomes of black women. BMC Public Health. 2022 Jan.22(1):193. Pubmedid: 35090433. Pmcid: PMC8795937.
  • Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022 Jan.55(1):115-128.e9. Pubmedid: 35021053. Pmcid: PMC8852221.
  • Nakamura K, Reid BM, Chen A, Chen Z, Goode EL, Permuth JB, Teer JK, Tyrer J, Yu X, Kanetsky PA, Pharoah PD, Gayther SA, Sellers TA, Lawrenson K, Karreth FA. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer. Am J Hum Genet. 2022 Jan.109(1):116-135. Pubmedid: 34965383. Pmcid: PMC8764204.
  • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
  • Li K, Yao S, Zhang Z, Cao B, Wilson CM, Kalos D, Kuan PF, Zhu R, Wang X. Efficient gradient boosting for prognostic biomarker discovery. Bioinformatics. 2022 Jan. Pubmedid: 34978570.
  • Malachowski SJ, Moy A, Messina J, Chen YA, Sun J, Sokol L, Seminario-Vidal L. Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns. J Am Acad Dermatol. 2022 Jan.86(1):186-188. Pubmedid: 33476732.
  • Jain RK, Skelton Iv WP, Pond GR, Naqvi M, Kim Y, Curran C, Freeman D, Nuzzo PV, Alaiwi SA, Nassar AH, Jain RK, Sonpavde G. Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2021 Dec.19(6):540-546. Pubmedid: 34011489. Pmcid: PMC8526625.
  • Wang Z, Guo R, Trudeau SJ, Wolinsky E, Ast T, Liang JH, Jiang C, Ma Y, Teng M, Mootha V, Gewurz B. CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival. Blood. 2021 Dec.138(22):2216-2230. Pubmedid: 34232987. Pmcid: PMC8641094.
  • Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021 Dec.56(12):2897-2903. Pubmedid: 34381169.
  • Huang BJ, Smith J, Wang J, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing RB, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, Cooper T, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ, Alonzo T, Ma X, Meshinchi S. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Adv. 2021 Dec.5(23):4963-4968. Pubmedid: 34547772. Pmcid: PMC9153007.
  • Teng M, Du D, Chen D, Irizarry RA. Characterizing batch effects and binding site-specific variability in ChIP-seq data. NAR Genom Bioinform. 2021 Dec.3(4):lqab098. Pubmedid: 34661103. Pmcid: PMC8515842.